P53 and nasopharyngeal carcinoma: A Malaysian study

Pathology

Volumn 41, Issue 6, 2009, Pages 561-565

  Hoe, S L L ^a   Lee, E S ^b   Khoo, A S B ^a   Peh, S C ^b  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

EBV; NPC; P53 expression; P53 mutation

Indexed keywords

PROTEIN P53;

ARTICLE; DNA BINDING; DNA SEQUENCE; EPSTEIN BARR VIRUS; EXON; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALAYSIA; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 70350658262     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020903071504     Document Type: Article

References (38)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. 2nd version. Lyon: IARC Press, 2004.
2. Lim GCC, Halimah Y. Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. Kuala Lumpur: National Cancer Registry, 2004; Chapter 2, Selected cancer sites 2003.
3. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893
4. Van Tornout JM, Spruck CH 3rd, Shibata A, et al. Presence of p53 mutations in primary nasopharyngeal carcinoma (NPC) in non-Asians of Los Angeles, California, a low-risk population for NPC. Cancer Epidemiol Biomark Prev 1997; 6: 493-497
5. Lo KW, Mok CH, Huang DP, et al. p53 mutation in human nasopharyngeal carcinomas. Anticancer Res 1992; 12: 1957-1963
6. Chakrani F, Armand JP, Lenoir G, et al. Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from southeastern Asia. Int J Cancer 1995; 61: 316-320
7. Taweevisit M. Overexpression of p53 and neoplastic cell proliferation in undifferentiated nasopharyngeal carcinoma. Southeast Asian J Trop Med Public Health 2007; 38: 136-140
8. Porter MJ, Field JK, Lee JC, et al. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res 1994; 14: 1357-1360
9. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15-30.
10. Kim LH, Peh SC. Epstein-Barr virus-associated lymphomas in Malaysia: high frequency of a 30-bp deletion in the viral Latent Membrane Protein-1 (LMP-1) oncogene. J Clin Exp Hematopthol 2003; 43: 11-19.
11. Chang KP, Hao SP, Lin SY, et al. A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy. Laryngoscope 2002; 112: 2015-2019
12. Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 2006; 103: 976-981
13. Concin N, Zeillinger C, Tong D, et al. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003; 79: 37-46.
14. Edwards RH, Raab-Traub N. Alterations of the p53 gene in Epstein- Barr virus-associated immunodeficiency-related lymphomas. J Virol 1994; 68: 1309-1315
15. Hoe SL, Sam CK. Mutational analysis of p53 and RB2/p130 genes in Malaysian nasopharyngeal carcinoma samples: a preliminary report. Malays J Pathol 2006; 28: 35-39
16. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16: 10881-10890
17. Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165
18. Sun Y, Hegamyer G, Cheng YJ, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1992; 89: 6516-6520
19. Nasrin N, Taiba K, Hannan N, et al. A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. Cancer Lett 1994; 82: 189-198
20. Khabir A, Sellami A, Sakka M, et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000; 6: 3932-3936
21. Agaoglu FY, Dizdar Y, Dogan O, et al. P53 overexpression in nasopharyngeal carcinoma. In Vivo 2004; 18: 555-560
22. Kropveld A, Rozemuller EH, Leppers FG, et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999; 79: 347-353
23. Hartmann A, Blaszyk H, McGovern RM, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995; 10: 681-688
24. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 1971-1981
25. Barber LM, McGrath HE, Meyer S, et al. Constitutional sequence variation in the Fanconi anaemia group C (FANCC) gene in childhood acute myeloid leukaemia. Br J Haematol 2003; 121: 57-62.
26. Gross E, Arnold N, Goette J, et al. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999; 105: 72-78
27. Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995; 55: 1448-1451
28. MacGeoch C, Barnes DM, Newton JA, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11: 239-250
29. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431-441
30. Rickinson A, Kie. E. Fields Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2007; Chapter 68A, Epstein-Barr virus and its replication.
31. Vera-Sempere FJ, Burgos JS, Botella MS, et al. Immunohistochemical expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1) in parafin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Eur J Cancer B Oral Oncol 1996; 32B: 163-168
32. Lin SY, Tsang NM, Kao SC, et al. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001; 23: 194-200.
33. Li L, Zhou S, Chen X, et al. The activation of p53 mediated by Epstein-Barr virus latent membrane protein 1 in SV40 large T-antigen transformed cells. FEBS Lett 2008; 582: 755-762
34. Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994; 14: 1929-1938
35. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001; 11: 23-30.
36. Sun Y, Yi H, Zhang PF, et al. Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 2007; 581: 131-139
37. Kouvidou C, Kanavaros P, Papaioannou D, et al. Expression of bcl-2 and p53 proteins in nasopharyngeal carcinoma. Absence of correlation with the presence of EBV encoded EBER1-2 transcripts and latent membrane protein-1. Clin Mol Pathol 1995; 48: M17-M22.
38. Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002; 94: 1997-2006.